Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhusha Anshen Wan is a traditional Chinese medicine (TCM) formula used for its sedative and tranquilizing properties. Manufactured by Liaoning Jindan Pharmaceutical, it is an approved product in China indicated for heart-fire hyperactivity and deficiency of heart-yin and blood. These conditions typically manifest as insomnia, palpitations, anxiety, and dream-disturbed sleep. The formula is a combination of several ingredients, most notably cinnabar (mercuric sulfide), which provides the primary sedative effect, and Coptis chinensis, which clears heart-fire. Other components like Angelica sinensis and Rehmannia glutinosa work to nourish the blood and yin, respectively, while Glycyrrhiza uralensis harmonizes the formula. It is traditionally administered as oral pills.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhusha anshen wan.